Ad
related to: medtronic surescan neurostimulator mri safety system
Search results
Results from the WOW.Com Content Network
Medical device maker Medtronic announced in a press release yesterday that it has won FDA regulatory approval for its Advisa DR MRI SureScan pacemaker. The Advisa is Medtronic's second MR ...
A spinal cord stimulator (SCS) or dorsal column stimulator (DCS) is a type of implantable neuromodulation device (sometimes called a "pain pacemaker") that is used to send electrical signals to select areas of the spinal cord (dorsal columns) for the treatment of certain pain conditions.
The ACR White Paper on MR Safety has been rewritten and was released early in 2007 under the new title ACR Guidance Document for Safe MR Practices. In December 2007, the Medicines and Healthcare products Regulatory Agency (MHRA), a UK healthcare regulatory body, issued their Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical ...
Medtronic's (MDT) first-of-its-kind Percept PC DBS system with the next-generation BrainSense technology clears FDA hurdle, paving the way for data-driven neurostimulation treatment.
The DBS system consists of three components: an implanted pulse generator (IPG), its leads and an extension. The IPG is a battery -powered neurostimulator encased in a titanium housing, which sends electrical pulses to the brain that interfere with neural activity at the target site.
Medical device maker Medtronic announced in a press statement Monday that it has begun a clinical trial testing neurostimulation therapy of its Specify 5-6-5 spinal cord stimulation treatment.
Neurostimulation for chronic pain is primarily through the use of spinal cord stimulators. [11] These devices deliver electrical stimulation to different areas of the spine based on where they are implanted. Since 2012, Medtronic has produced spinal cord stimulators with accelerometers that can predict the patient's position. The device can be ...
Medtronic and Neuromed also made deep brain stimulators at the time, but reportedly felt a complex safety and efficacy clinical trial in patients who were difficult to evaluate would be too costly for the size of the potential patient base, so did not submit clinical data on DBS for chronic pain to the FDA, and that indication was de-approved.
Ad
related to: medtronic surescan neurostimulator mri safety system